Lithium: Independent Evidence on Bipolar, Suicide & Kidney Risk
Lithium is the best-proven long-term treatment for bipolar disorder, but its narrow safe range means regular blood tests for levels, kidneys, thyroid and calcium.
Independent research on stress, anxiety and depression — supplement and lifestyle claims graded honestly, with funding and conflicts made transparent.
Lithium is the best-proven long-term treatment for bipolar disorder, but its narrow safe range means regular blood tests for levels, kidneys, thyroid and calcium.
MAOI antidepressants work about as well as newer drugs, with an edge in atypical depression, but carry specific tyramine, interaction and supply risks.
Lofepramine is the tricyclic antidepressant NICE treats as an exception for overdose safety. We weigh its old trial evidence, heart and liver risks, and who funded the research.
Imipramine, the first tricyclic, works for adult depression and panic, but bedwetting relapses after stopping and overdose is dangerous.
Clomipramine works for OCD but is not clearly better than SSRIs, and carries heavier side effects, seizure and overdose risks. We trace the evidence and the money.
Guided digital CBT and insomnia programmes work; self-help apps and chatbots help less than claimed. We review the trials, NICE and FDA decisions, privacy cases and who paid for the evidence.
EMDR therapy works for adult PTSD about as well as trauma-focused CBT. We review the eye-movement debate, children, other uses, risks and who funds the research.
Yoga eases depressive symptoms about as much as other exercise and helps anxiety a little, but it fell short of CBT in the largest anxiety trial.
Psilocybin therapy eased treatment-resistant depression in company-funded trials, but the gain over control was modest, blinding is weak and no regulator has approved it yet.
MBCT helps prevent depression relapse and mindfulness courses modestly ease anxiety and stress. We trace who funded the trials, the harms, and the weaker claims.
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.